Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)

Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms REFLEX
  • Sponsors Merck KGaA
  • Most Recent Events

    • 25 Sep 2018 Results of pooled data from 17 clinical trials and post-marketing surveillance, were published in the Advances in Therapy.
    • 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology
    • 28 Oct 2017 Results of post hoc analysis of REFLEX and REFLEXION trials assessing the impact of gadolinium-enhancing (Gd+) lesions at baseline on NEDA presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top